ArticleUrology2016

Nivolumab: The New Second Line Treatment for Advanced Renal-cell Carcinoma Commentary on: Nivolumab Versus Everolimus in Advanced Renal-cell Carcinoma.

Edmund C P Chedgy et al.PubMed ↗Publisher ↗

No numbers read from the abstract.